Ferrous iron-dependent delivery of therapeutic agents to the malaria parasite

Future Medicinal Chemistry

Volumn 4, Issue 18, 2012, Pages 2241-2249

  Mahajan, Sumit S ^a   Gut, Jiri ^a   Rosenthal, Philip J ^a   Renslo, Adam R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 TRIOXANE DERIVATIVE; ANTIMALARIAL AGENT; ENDOPEROXIDE; FERROUS ION;

ANTIMALARIAL ACTIVITY; ARTICLE; CHEMICAL STRUCTURE; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG TARGETING; FRAGMENTATION REACTION; IC 50; IN VITRO STUDY; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL;

ANIMALS; ANTIMALARIALS; DRUG DELIVERY SYSTEMS; ERYTHROCYTES; FERROUS COMPOUNDS; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PRODRUGS;

EID: 84871053194     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.174     Document Type: Article

References (28)

1. Rosenthal PJ. Cysteine proteases of malaria parasites. Int. J. Parasitol. 34(13-14), 1489-1499 (2004).
2. Yayon A, Timberg R, Friedman S, Ginsburg H. Effects of chloroquine on the feeding mechanism of the intraerythrocytic human malarial parasite Plasmodium falciparum. J. Protozool 31(3), 367-372 (1984). (Pubitemid 14020760)
3. Robert A, Benoit-Vical F, Meunier B. The key role of heme to trigger the antimalarial activity of trioxanes. Coord. Chem. Rev. 249(17-18), 1927-1936 (2005). (Pubitemid 41121959)
4. Charman SA, Arbe-Barnes S, Bathurst IC et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc. Natl Acad. Sci. USA 108(11), 4400-4405 (2011).
5. O'Neill PM, Posner GH. A medicinal chemistry perspective on artemisinin and related endoperoxides. J. Med. Chem. 47(12), 2945-2964 (2004). (Pubitemid 38702690)
6. Hartwig CL, Rosenthal AS, D'angelo J, Griffin CE, Posner GH, Cooper RA. Accumulation of artemisinin trioxane derivatives within neutral lipids of Plasmodium falciparum malaria parasites is endoperoxide-dependent. Biochem. Pharmacol. 77(3), 322-336 (2009).
7. Hartwig CL, Lauterwasser EM, Mahajan SS, Hoke JM, Cooper RA, Renslo AR. Investigating the antimalarial action of 1,2,4-trioxolanes with fluorescent chemical probes. J. Med. Chem. 54(23), 8207-8213 (2011).
8. Creek DJ, Charman WN, Chiu FC et al. Relationship between antimalarial activity and heme alkylation for spiro-and dispiro-1,2,4-trioxolane antimalarials. Antimicrob. Agents. Chemother. 52(4), 1291-1296 (2008). (Pubitemid 351521990)
9. Meunier B. Hybrid molecules with a dual mode of action: dream or reality? Acc. Chem. Res. 41(1), 69-77 (2008).
10. Robert A, Benoit-Vical F, Claparols C, Meunier B. The antimalarial drug artemisinin alkylates heme in infected mice. Proc. Natl Acad. Sci. USA 102(38), 13676-13680 (2005). (Pubitemid 41420907)
11. Bousejra-El Garah F, Claparols C, Benoit-Vical F, Meunier B, Robert A. The antimalarial trioxaquine DU1301 alkylates heme in malaria-infected mice. Antimicrob. Agents Chemother. 52(8), 2966-2969 (2008).
12. Pradines V, Portela J, Boissier J, Cosledan F, Meunier B, Robert A. Trioxaquine PA1259 alkylates heme in the blood-feeding parasite Schistosoma mansoni. Antimicrob. Agents Chemother. 55(5), 2403-2405 (2011).
13. Chadwick J, Amewu RK, Marti F et al. Antimalarial mannoxanes: hybrid antimalarial drugs with outstanding oral activity profiles and a potential dual mechanism of action. ChemMedChem 6(8), 1357-1361 (2011).
14. Feng TS, Guantai EM, Nell M et al. Effects of highly active novel artemisinin-chloroquinoline hybrid compounds on beta-hematin formation, parasite morphology and endocytosis in Plasmodium falciparum. Biochem. Pharmacol. 82(3), 236-247 (2011).
15. Capela R, Cabal GG, Rosenthal PJ et al. Design and evaluation of primaquine-artemisinin hybrids as a multistage antimalarial strategy. Antimicrob. Agents Chemother. 55(10), 4698-4706 (2011).
16. Slack RD, Jacobine AM, Posner GH. Antimalarial peroxides: advances in drug discovery and design. MedChemComm 3(3), 281-297 (2012).
17. Mahajan SS, Deu E, Lauterwasser EM et al. A fragmenting hybrid approach for targeted delivery of multiple therapeutic agents to the malaria parasite. ChemMedChem 6(3), 415-419 (2011).
18. O'Neill PM, Stocks PA, Pugh MD et al. Design and synthesis of endoperoxide antimalarial prodrug models. Angew. Chem. Int. Ed. Engl. 43(32), 4193-4197 (2004). (Pubitemid 39257436)
19. O'Neill PM, Mukhtar A, Ward SA et al. Application of thiol-olefin co-oxygenation methodology to a new synthesis of the 1,2,4-trioxane pharmacophore. Org. Lett. 6(18), 3035-3038 (2004). (Pubitemid 39233113)
20. Vennerstrom JL, Arbe-Barnes S, Brun R et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430(7002), 900-904 (2004). (Pubitemid 39119218)
21. Stocks PA, Bray PG, Barton VE et al. evidence for a common non-heme chelatable-iron-dependent activation mechanism for semisynthetic and synthetic endoperoxide antimalarial drugs. Angew. Chem. Int. Ed. Engl. 46(33), 6278-6283 (2007). (Pubitemid 47329416)
22. Rosenthal PJ, Mckerrow JH, Aikawa M, Nagasawa H, Leech JH. A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum. J. Clin. Invest. 82(5), 1560-1566 (1988). (Pubitemid 19007759)
23. Shenai BR, Lee BJ, Alvarez-Hernandez A et al. Structure-activity relationships for inhibition of cysteine protease activity and development of Plasmodium falciparum by peptidyl vinyl sulfones. Antimicrob. Agents Chemother. 47(1), 154-160 (2003). (Pubitemid 36070357)
24. Fonovic M, Bogyo M. Activity-based probes as a tool for functional proteomic analysis of proteases. Expert Rev. Proteomics 5(5), 721-730 (2008).
25. Johnson DS, Weerapana E, Cravatt BF. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Future Med. Chem. 2(6), 949-964 (2010).
26. Deu E, Leyva MJ, Albrow VE, Rice MJ, Ellman JA, Bogyo M. Functional studies of Plasmodium falciparum dipeptidyl aminopeptidase I using small molecule inhibitors and active site probes. Chem. Biol. 17(8), 808-819 (2010).
27. Santi DV, Schneider EL, Reid R, Robinson L, Ashley GW. Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates. Proc. Natl Acad. Sci. USA 109, 6211-6216 (2012).
28. Gibbons P, Verissimo E, Araujo NC et al. Endoperoxide carbonyl falcipain 2/3 inhibitor hybrids: toward combination chemotherapy of malaria through a single chemical entity. J. Med. Chem. 53(22), 8202-8206 (2010).